Semaglutide pyridoxine is usually a compounded injection containing semaglutide and pyridoxine, a common supplemental form of vitamin B6. Some compounding pharmacies include B6 with nausea support in mind. The ingredients remain separate substances, and no published clinical trial has shown that adding pyridoxine prevents semaglutide-related nausea or improves semaglutide's effects. Formulations vary by pharmacy and prescription, so the dispensing label—not the product category—determines what is in a specific vial.
What semaglutide pyridoxine means on a label
In the name "semaglutide/pyridoxine," semaglutide is the prescription drug ingredient. Pyridoxine is one of the forms of vitamin B6; the body converts B6 into coenzyme forms involved in amino-acid metabolism, neurotransmitter synthesis and other processes. The NIH vitamin B6 fact sheet identifies pyridoxine hydrochloride as the most common B6 form in supplements.
Putting both ingredients in one preparation does not create a new molecule. It creates a combination with a pharmacy-specific concentration and ratio. The label should name both active ingredients, state the amount of each per unit of volume and identify the pharmacy. One pharmacy's semaglutide/B6 formula should not be assumed to match another's.
Semaglutide offered through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Compounded products do not undergo FDA premarket review for safety, effectiveness and quality. Our guide to compounded semaglutide explains that distinction in detail.
Why vitamin B6 is added to semaglutide
The rationale starts with a real semaglutide issue. In the 1,961-person STEP 1 trial, nausea and diarrhea were the most common adverse events and were generally transient and mild to moderate. Gastrointestinal events led 4.5% of participants taking semaglutide to stop treatment, compared with 0.8% taking placebo (Wilding et al., New England Journal of Medicine 2021). That establishes the reason someone might look for nausea support. It does not establish that B6 supplies it.
The pyridoxine evidence comes from pregnancy, not GLP-1 treatment. A 1995 randomized, double-blind trial assigned 342 pregnant women to oral pyridoxine or placebo for five days. Nausea scores improved more with pyridoxine, while the difference in vomiting episodes did not reach statistical significance (Vutyavanich et al., American Journal of Obstetrics and Gynecology 1995).
A later randomized trial included 92 women hospitalized with hyperemesis gravidarum. Adding oral pyridoxine to standard therapy did not improve nausea scores, vomiting frequency or rehospitalization over two weeks (Tan et al., Gynecologic and Obstetric Investigation 2009).
Those studies involved different patients, routes and causes of nausea. As of September 2026, no published randomized trial has compared semaglutide/pyridoxine with semaglutide alone. The evidence therefore supports a limited conclusion: B6 has been studied for pregnancy-related nausea, but its value for GLP-1 nausea is unknown. How long GLP-1 nausea lasts covers the usual pattern and when symptoms deserve prompt medical attention.
Pyridoxine, B12 and other additives are not interchangeable
Compounded semaglutide may be prepared with different additional ingredients. Their names and rationales cannot be swapped. A vitamin's established nutritional role also does not show that it changes semaglutide's weight, glucose or tolerability outcomes.
| Additive | What it is | Why it may appear | What has not been established |
|---|---|---|---|
| Pyridoxine | Vitamin B6 | Nausea-support rationale borrowed from pregnancy care | That it prevents semaglutide-related nausea |
| Cyanocobalamin or methylcobalamin | Forms of vitamin B12 | Nutritional adjunct | That it increases semaglutide's effects |
| Niacinamide | A form of vitamin B3 | Nutritional adjunct | That it changes semaglutide tolerability |
The exact formulation is a prescribing and dispensing fact, not something to infer from a telehealth brand or a general semaglutide product overview. The prescription and pharmacy label are the sources of truth.
B6 is not automatically harmless because it is a vitamin. Long-term high exposure can cause sensory neuropathy, including numbness, tingling and balance problems. The NIH fact sheet sets the U.S. adult upper limit from food and supplements at 100 mg per day, while noting that this limit does not apply to medically supervised treatment. A provider needs to consider the compounded preparation alongside multivitamins, B-complex products and other B6 sources.
Why the additive matters under compounding rules
As of September 2026, FDA's April 1, 2026 GLP-1 compounding update says section 503A pharmacies compound for an identified patient based on a prescription and may not regularly make products that are essentially copies of commercially available drugs. An exception can apply when the prescriber determines and documents that a change produces a significant difference for that patient.
FDA's example uses semaglutide combined with B12. It shows why a second ingredient is not a regulatory shortcut: the mere presence of an additive does not replace the patient-specific analysis. The clinical purpose of pyridoxine should be documented, not assumed from the slash on the label.
A licensed provider may still prescribe a compounded formulation when appropriate and lawful; that decision belongs to the patient and prescriber. At Promise, a licensed provider reviews every request, and not everyone qualifies.
The additive and the drug are separate decisions
A clear review resolves two questions: whether semaglutide is appropriate, and whether a particular B6-containing formulation creates a meaningful difference for the individual patient. Useful label questions include the exact ingredients and concentrations, why pyridoxine was selected, and how much B6 the person already receives from other sources.
Tirzepatide is a different GLP-1 medication, but the same additive question can appear on its labels. The sibling guide to tirzepatide/pyridoxine applies the same evidence boundary: pregnancy nausea data cannot establish a benefit inside a GLP-1 combination.
What deserves a straight answer
The ingredient line can confirm that pyridoxine is present. It cannot prove that the vitamin makes semaglutide stronger, gentler or more effective. A useful clinical explanation names the formulation, gives the patient-specific reason for it and separates that rationale from what trials have actually tested.
For semaglutide/pyridoxine, that boundary is clear: B6 has a mixed evidence base in pregnancy-related nausea and no randomized evidence for semaglutide-related nausea. Persistent or severe symptoms still require clinical review rather than an assumption that the additive will cover them.